<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81810">
  <stage>Registered</stage>
  <submitdate>15/01/2007</submitdate>
  <approvaldate>19/01/2007</approvaldate>
  <actrnumber>ACTRN12607000065493</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 21-99 - Menstrual Cycle and Surgical Treatment of Breast Cancer</studytitle>
    <scientifictitle>Menstrual Cycle and Surgical Treatment of Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>International Breast Cancer Study Group (IBCSG): IBCSG 21-99</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will undergo either a one-stage surgical procedure (open biopsy followed by mastectomy or breastconserving
approach) or two-stage surgical procedure (open biopsy followed later by mastectomy or breast-conserving approach) and will be followed every year for 10 years.</interventions>
    <comparator>No conrtol group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival</outcome>
      <timepoint>Patients will be assessed for progression of disease every 6 months for the first year after study entry and annually thereafter until year 10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Distant disease free-survival</outcome>
      <timepoint>Patients will be assessed for progression of disease and survival status every 6 months for the first year after study entry and annually thereafter until year 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Patients will be assessed for progression of disease and survival status every 6 months for the first year after study entry and annually thereafter until year 10.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>One-stage surgical procedure (open biopsy followed by mastectomy or breast conserving approach):Required characteristics Premenopausal women with regular menstrual periods (2135 days) and pathologic stage III breast cancer. One-stage surgical procedure plus serum drawn within one calendar day of procedure. FNA, core needle, or stereotactic biopsy is allowed at any time prior to the one-stage procedure. Sentinel node dissection/axillary node dissection is also acceptable. The use of chemotherapy and/or radiation therapy is allowable according to the usual internationally accepted criteria. All gross disease removed including DCIS. Contraindications Pregnant women. Previous breast cancer. Any previous cancer. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exceptions: 1) &gt;10 years disease free or 2) squamous or basal cell skin carcinoma. Neoadjuvant treatment. Galactorrhea. Lactating within the past 3 months. Oral contraceptive use within the last 3 months. Stage III or IV disease.Two-stage surgical procedure (open biopsy followed later by mastectomy or breast-conserving approach):Required characteristics: Pathologic stage I-II breast cancer. Premenopausal women with regular menstrual periods (2135 days). Undergoing a two-stage surgical procedure. Serum drawn within one calendar day of open biopsy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/1996</anticipatedstartdate>
    <actualstartdate>1/11/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/12/2001</actualenddate>
    <samplesize>884</samplesize>
    <actualsamplesize>1118</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>North Central Cancer Treatment Group</primarysponsorname>
    <primarysponsoraddress>NCCTG
Operations Office
200 First Street SW
Rochester, MN 55905</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australia and New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>International Breast Cancer Study Group</sponsorname>
      <sponsoraddress>International Breast Cancer Study Group Effingerstrasse 40
CH-3008 Bern, Switzerland</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>National Surgical Adjuvant Breast and Bowel Project</sponsorname>
      <sponsoraddress>NSABP Foundation, Inc.
Four Allegheny Center, Fifth Floor
Pittsburgh, PA 15212-5234</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australia and New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>PO BOX 155
 HRMC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate whether the timing of breast cancer surgery during a womans menstrual cycle affects her ultimate outcome- the likelihood of recurrence of breast cancer or death from breast cancer. This study involves taking a small sample of blood from the woman close to her surgery to evaluate her menstrual phase on the basis of hormones in her blood. The woman will then go on to have whichever treatments for her breast cancer that she decides with her doctor. The woman will  be observed for at least 5 years and information regarding her treatment and disease progression will be submitted.</summary>
    <trialwebsite>http://www.anzbctg.org/</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/11/1999</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax>+ 61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+ 61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
 HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>